Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes
International Journal of Cancer, 04/30/2012
Carretero R et al. – The authors favor the idea that the major factor determining the success or failure of immunotherapy is the nature of HLA Class I alterations in tumor cells and not the type of immunotherapy used. If the molecular alteration is reversible by the immunotherapy, the HLA expression will be upregulated and the lesion will be recognized and rejected. In contrast, if the defect is structural the MHC Class I expression will remain unchanged and the lesion will progress.



